ADA 2009 Recommendations Reaffirm Acceptance of Low Carb Diet Diabetes Health (press release), CA - How a patient moves from metformin to a sulfonylurea or combination product and then on to Januvia, Byetta , or insulin is left up to the medical ... Know You Numbers, Outlive Your Diabetes author interview (part 3)

LegalView Updates its Baxter Heparin Information Portal TransWorldNews (press release), GA - LegalView also offers several additional pharmaceutical practice areas on an array of topics ranging from Avandia and Byetta to the recent Chantix ... LegalView Reports FDA Delay of Drug That Might Prevent

Byetta Review for Stand-Alone Use Delayed, Companies Say FDA news (subscription), VA - The FDA probably will not complete its review of Eli Lilly and Amylin Pharmaceuticals Type 2 diabetes drug Byetta by the end of this year, the companies ...

SmartAboutHealth Sector Snap: Diabetes drugs could see FDA pressure Forbes, NY - "We believe upon meta-analysis that Byetta , and as an extension, exenatide LAR, will show minimal or no increase of cardiovascular event risk," said Lazard ... FDA Wants Longer, Tougher Diabetes Drug Clinical Trials Diabetes Drugs to Face Tougher Risk Scrutiny

Diabetes Health (press release) FDA Unlikely to Approve Byetta Monotherapy Soon Diabetes Health (press release), CA - Hopes that the US Food and Drug Administration would move soon to make the diabetes drug Byetta a monotherapy are fading. It now appears that the FDA will ...

Amylin advances further on hopes for diabetes drug Forbes, NY - Amylin is developing exenatide long-acting release, or LAR, with Eli Lilly & Co. and Alkermes Inc. LAR is a once-weekly form of Byetta , a drug Amylin and ... Amylin Gets Some FDA Love Russell opens in the red; CEA, ZNH, and AMLN lead gainers

Amylin jumps 30 pct on Byetta LAR diabetes news Trading Markets (press release), CA - Byetta LAR, as the long-acting version is called, hit a regulatory snag in November when the US Food and Drug Administration rejected some data on the ... Amylin shares rise on prospects for exenatide LAR Amylin Shares Soar as Diabetes Drug Catches a Break From FDA Amylin Pharmaceuticals (AMLN) NewsBite - AMLN Rises on Drug ... -

Eli Lilly's Lechleiter: "Ludicrous" Stock Price CNBC, Englewood Cliffs - () that they're on track to file for FDA approval of a once-a-week version of their diabetes drug Byetta by the end of the first half of next year. ... Lilly Looks Healthy Lilly unveils blueprint to trim costs, boost drugs Lilly view provides relief, diabetes drug on track -

Lilly Highlights Transformation Strategy for Wall Street, Reviews ... MarketWatch - Byetta , which the company markets along with its partner, Amylin Pharmaceuticals, has now been used by more than 1 million patients worldwide. ...

US Recall News (press release) Byetta Recall US Recall News (press release), CO - There seems to be a lot of interest from visitors about a possible Byetta Recall so we wanted to provide some information about what is happening with this ...